SOURCE: Quidel


February 24, 2015 17:00 ET

Quidel to Present at Upcoming Conferences

SAN DIEGO, CA--(Marketwired - Feb 24, 2015) -  Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the following conferences:

  • Cowen and Company 35th Annual Health Care Conference, to be held at the Boston Marriott Copley Place hotel in Boston, Massachusetts, on March 4, 2015 at 11:20 a.m. Eastern time (8:20 a.m. Pacific time).

  • Barclays Global Healthcare Conference, to be held at the Loews Miami Beach hotel in Miami, Florida, on March 12, 2015 at 2:05 p.m. Eastern time (11:05 a.m. Pacific time).

Douglas Bryant, president and chief executive officer, will present on the specified dates and times with a question-and-answer session scheduled immediately following each presentation. During the presentations, the company will discuss business and financial developments and trends. The company's statements may contain or constitute material information that has not been previously disclosed.

A live webcast and audio archive of each presentation will be available via the Investor Relations section of the company's Web site at Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the company's Web site for 14 days.

About Quidel Corporation
Quidel Corporation serves to enhance the health and wellbeing of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the QuickVue®, D3® Direct Detection and Thyretain® leading brand names, as well as under the new Sofia®, AmpliVue® and Lyra® brands, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit

Contact Information

  • Quidel Contact:
    Quidel Corporation
    Randy Steward
    Chief Financial Officer
    (858) 552-7931

    Media and Investors Contact:
    Quidel Corporation
    Ruben Argueta
    (858) 646-8023
    Email Contact